Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34


A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.

Boyle TA, Quinn GP, Schabath MB, Muñoz-Antonia T, Saller JJ, Duarte LF, Hair LS, Teer JK, Chiang DY, Leary R, Wong CC, Savchenko A, Singh AP, Charette L, Mendell K, Gorgun G, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Haura EB.

Cancer Med. 2020 Jan;9(1):225-237. doi: 10.1002/cam4.2670. Epub 2019 Nov 20.


Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model.

Sarcar B, Gimbrone NT, Wright G, Remsing Rix LL, Gordian ER, Rix U, Chiappori AA, Reuther GW, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD.

FEBS Open Bio. 2019 Oct;9(10):1689-1704. doi: 10.1002/2211-5463.12702. Epub 2019 Sep 7.


Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.

Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB.

Br J Cancer. 2019 Apr;120(8):791-796. doi: 10.1038/s41416-019-0428-3. Epub 2019 Mar 18.


Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ.

Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27.


Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.

Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, Riely GJ, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT.

ESMO Open. 2018 Jul 12;3(5):e000364. doi: 10.1136/esmoopen-2018-000364. eCollection 2018.


Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program.

Quinn GP, Pentz RD, Muñoz-Antonia T, Boyle TA, Schabath MB, Pratt CL, Shaffer A, Duarte LF, Bowman-Curci M, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Williams CC, Haura EB.

Patient Educ Couns. 2018 Apr;101(4):703-710. doi: 10.1016/j.pec.2017.11.014. Epub 2017 Nov 28.


A Bayesian pick-the-winner design in a randomized phase II clinical trial.

Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE.

Oncotarget. 2017 Jul 7;8(51):88376-88385. doi: 10.18632/oncotarget.19088. eCollection 2017 Oct 24.


Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.

Gimbrone NT, Sarcar B, Gordian ER, Rivera JI, Lopez C, Yoder SJ, Teer JK, Welsh EA, Chiappori AA, Schabath MB, Reuther GW, Dutil J, Garcia M, Ventosilla-Villanueva R, Vera-Valdivia L, Yabar-Berrocal A, Motta-Guerrero R, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD.

J Thorac Oncol. 2017 Dec;12(12):1851-1856. doi: 10.1016/j.jtho.2017.08.019. Epub 2017 Sep 11.


Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.

Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD.

Oncotarget. 2016 Dec 13;7(50):82254-82265. doi: 10.18632/oncotarget.12672.


A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist. 2016 Oct;21(10):1163-1164. Epub 2016 Sep 30.


Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM.

Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8.


Longitudinal cohort study to determine effectiveness of a novel simulated case and feedback system to improve clinical pathway adherence in breast, lung and GI cancers.

Kubal T, Letson DG, Chiappori AA, Springett GM, Shimkhada R, Tamondong Lachica D, Peabody JW.

BMJ Open. 2016 Sep 13;6(9):e012312. doi: 10.1136/bmjopen-2016-012312.


Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis.

Hembree TN, Teer JK, Hakam A, Chiappori AA.

Cancer Control. 2016 Jan;23(1):61-6.


A phase I study of indoximod in patients with advanced malignancies.

Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ.

Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216.


Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma.

Raj S, Bui MM, Springett G, Conley A, Lavilla-Alonso S, Zhao X, Chen D, Haysek R, Gonzalez R, Letson GD, Finkelstein SE, Chiappori AA, Gabrilovitch DI, Antonia SJ.

Sarcoma. 2015;2015:614736. doi: 10.1155/2015/614736. Epub 2015 Dec 31.


Propelling Immunotherapy Combinations Into the Clinic.

Tchekmedyian N, Gray JE, Creelan BC, Chiappori AA, Beg AA, Soliman H, Perez BA, Antonia SJ.

Oncology (Williston Park). 2015 Dec;29(12):990-1002. Review.


A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, Bassett E, Burington B, Schiller JH.

Ann Oncol. 2015 Feb;26(2):354-62. doi: 10.1093/annonc/mdu550. Epub 2014 Dec 2.


Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.

Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.


Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients.

Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ, Chiappori AA.

Lung Cancer. 2014 Oct;86(1):14-21. doi: 10.1016/j.lungcan.2014.07.014. Epub 2014 Jul 27.


Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer.

Tanvetyanon T, Creelan BC, Chiappori AA.

Cancer Control. 2014 Jan;21(1):32-9. Review.


Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings.

Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA.

Clin Nucl Med. 2013 Mar;38(3):175-82. doi: 10.1097/RLU.0b013e318279ffdf.


Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.

Hall RD, Gray JE, Chiappori AA.

Cancer Control. 2013 Jan;20(1):22-31. Review.


A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.

Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS.

Br J Cancer. 2012 Feb 28;106(5):839-45. doi: 10.1038/bjc.2012.21. Epub 2012 Feb 14.


INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.

Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI.

Expert Opin Biol Ther. 2010 Jun;10(6):983-91. doi: 10.1517/14712598.2010.484801. Review.


Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.

Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA.

Cancer. 2010 Mar 15;116(6):1582-91. doi: 10.1002/cncr.24927.


Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.

Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G.

J Thorac Oncol. 2010 Apr;5(4):484-90. doi: 10.1097/JTO.0b013e3181ccb27b.


Increased cyclin D3 expression significantly correlates with p27 nuclear positivity in gastrointestinal stromal tumors.

Draper N, Bui M, Boulware DC, Lloyd M, Chiappori AA, Pledger WJ, Coppola D.

Hum Pathol. 2008 Dec;39(12):1784-91. doi: 10.1016/j.humpath.2008.05.007. Epub 2008 Aug 12.


Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G.

Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508.


Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.

Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI.

Clin Cancer Res. 2007 Oct 1;13(19):5855-61.


Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

Jänne PA, von Pawel J, Cohen RB, Crino L, Butts CA, Olson SS, Eiseman IA, Chiappori AA, Yeap BY, Lenehan PF, Dasse K, Sheeran M, Bonomi PD.

J Clin Oncol. 2007 Sep 1;25(25):3936-44.


A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.

Chiappori AA, Ellis PM, Hamm JT, Bitran JD, Eiseman I, Lovalvo J, Burnett D, Olson S, Lenehan P, Zinner RG.

J Thorac Oncol. 2006 Nov;1(9):1010-9.


A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.

Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ.

Clin Cancer Res. 2007 Apr 1;13(7):2091-9.


Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.

Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM.

Clin Cancer Res. 2006 Jan 15;12(2):523-8.


New agents in the treatment of small-cell lung cancer: focus on gemcitabine.

Chiappori AA, Rocha-Lima CM.

Clin Lung Cancer. 2003 Jan;4 Suppl 2:S56-63.


Supplemental Content

Loading ...
Support Center